2-Day Detox Study

2-Day Detox Study


We are seeking approximately 30 participants to take part in a 16-day open-label pilot study evaluating the safety and efficacy of Qualia 2-Day Detox, a dietary supplement designed to support the body’s natural detoxification processes and overall well-being.

Participants will complete two 2-day supplement cycles separated by a 12-day break. During each cycle, participants will take the following formulas:

Participants will take four different formulas throughout the day: 4 capsules in the morning, 8 capsules with meals (may be split between lunch and dinner), 4 capsules on an empty stomach, and 1 capsule 30–60 minutes before bedtime.

The study will include self-report questionnaires assessing safety, tolerability, and changes in quality of life and toxicity burden from baseline to the end of the study.

Upon completion of all study requirements, participants will receive a $200 credit at Qualia Life Sciences as a thank-you for their time and participation.


*US only

*This study is being conducted by Qualia Life Science

Pre-screening surveys are used solely to determine eligibility for participation. 

Data will be securely stored on Qualia Life Sciences servers, accessible only to authorized personnel.


Participation Requirements:

  • Provide voluntary, written, informed consent to participate in the study
  • Agree to provide a valid cell phone number and are willing to receive communications through text
  • Can read and write English
  • Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
  • Willing  to complete questionnaires, records, and diaries associated with the study.
  • MSQ score ≥ 20
  • Healthy males and females aged 25–59

Exclusion Criteria:

  • Women who are pregnant, breastfeeding, or planning to become pregnant or start breast feeding during the trial
  • Known food intolerances/allergy to any ingredients in the product
  • Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
  • Having had a significant cardiovascular event in the past 6 months
  • Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
  • On immunosuppressive therapy
  • Individuals who were deemed incompatible with the test protocol
  • Adults lacking capacity to consent
  • Blood clotting or coagulation disorders (e.g., hemophilia, thrombocytopenia)
  • History of ischemic stroke or recent stroke
  • History of deep vein thrombosis or other thrombotic disorders
  • Kidney Disease
  • Surgery within the past 6 weeks or upcoming planned surgery in the next few months
  • Taking any of the following medications:
  • Anticoagulants (blood thinners) such as warfarin, heparin, and enoxaparin (Lovenox).
  • Antiplatelet drugs like aspirin, clopidogrel (Plavix), ticlopidine (Ticlid), and other similar agents.
  • Fibrinolytic or thrombolytic drugs used to dissolve blood clots.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, indomethacin, naproxen, meloxicam
  • Insulin or oral diabetes medications

Note: Drug-specific interactions and history of deep vein thrombosis or other thrombotic disorders were added to the exclusion criteria because of nattokinase, which, while shown to be administered safely and without evidence of increased bleeding risk in human studies, carries a theoretical concern of interactions with medications or conditions involving the blood clotting system. See https://www.drugs.com/npp/nattokinase.html#interactions

This study is being conducted by Qualia Life Science

This beta test has been completed